Skip to main content

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

A phase I trial of ABTL0812 in paediatric patients with advanced cancer including neuroblastoma

IP: Lucas Moreno Martín-Retortillo
Collaborators: Soledad Gallego Melcón, Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez
Funding agency: Instituto de Salud Carlos III
Funding: 826760.77
Reference: ICI21/00076
Duration: 01/01/2022 - 30/06/2026

Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain

IP: Lucas Moreno Martín-Retortillo
Collaborators: Andrea Vilaplana Blanes, Aroa Soriano Fernández, Aroa Soriano Fernández, Margarita Ortega Blanco, Miguel Segura Ginard, Lorena Valero Arrese, Berta Campos Estela, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Estela Carrasco López, Gabriela Guillén Burrieza, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 369260
Reference: PMP21/00073
Duration: 01/01/2022 - 30/06/2026

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Collaborators: Andrea Vilaplana Blanes, Aroa Soriano Fernández, Jessica Camacho Soriano, Lorena Valero Arrese, Raquel Hladun Alvaro, Gabriela Guillén Burrieza
Funding agency: Instituto de Salud Carlos III
Funding: 214170
Reference: PI21/01661
Duration: 01/01/2022 - 30/06/2026

Quatsomes as a novel nanomaterial platform for nucleic acids delivery

IP: Miguel Segura Ginard
Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Lucas Moreno Martín-Retortillo
Funding agency: Instituto de Salud Carlos III
Funding: 83600
Reference: DTS20/00018
Duration: 01/01/2021 - 31/12/2022

Related news

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

Vall d'Hebron is one of the centers that coordinate this network, which so far has enabled the detection of high-risk genetic alterations and the provision of personalized treatments that have already achieved remission in cases with very few therapeutic alternatives.

The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.

Related professionals

Ana Díez Izquierdo

Ana Díez Izquierdo

Main researcher
Growth and Development
Read more
Maria Garcia Carrasco

Maria Garcia Carrasco

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Marta Comas Martinez

Marta Comas Martinez

Research technician
Read more
Mario Marotta Baleriola

Mario Marotta Baleriola

Senior researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.